Alto Neuroscience, Inc. Long-Term Debt, Maturity, Year Two
Alto Neuroscience, Inc. (ANRO) had Long-Term Debt, Maturity, Year Two of $5.23 million as of 2024-12-31, per its 10-K filed 2025-03-20.
Financial Statements › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity › Long-Term Debt, Maturity, Year Two and Three
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo · last filed 2025-03-20
- 2024-12-31: Long-Term Debt, Maturity, Year Two $5.23M.
- 2024-09-30: Long-Term Debt, Maturity, Year Two $5.23M.
- 2024-06-30: Long-Term Debt, Maturity, Year Two $5.23M.
- 2024-03-31: Long-Term Debt, Maturity, Year Two $5.23M.
| Period end | Long-Term Debt, Maturity, Year Two |
|---|---|
| 2024-12-31 | $5.23M 10-K · filed 2025-03-20 |
| 2024-09-30 | $5.23M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $5.23M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $5.23M 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |